Becton, Dickinson

Becton Dickinson Shareholders Approve All Proposals, Celebrate Record FY2025 Performance

Becton Dickinson Announces Executive Severance Plan and Equity Compensation Plan Amendment

Boston Scientific

Edwards Lifesciences

iShares U.S. Medical Devices ETF

iShares U.S. Medical Devices ETF Experiences Significant Outflow

Becton Dickinson's Valuation: Undervalued by 38.5%

碧迪医疗

BD and Envetec study opens door to sustainable recycling of medical plastics.

Catalyst<ul> <li>The company maintains strong cash reserves relative to market value.</li></ul>Risk<ul> <li>Bearish signals are obviously dominant with 6 bearish versus 1 bullish technical indicators.</li> <li>The technical side is weak suggesting a risk of decline according to recent indicators.</li> <li>Fund flow analysis shows negative overall trend with large and extra-large order inflow ratios below 50%.</li></ul>

Key Factors

Becton Dickinson shareholders approved all four proposals at the annual meeting, including director elections and an equity compensation plan amendment.BDX announced an Executive Severance Plan and amended its 2004 Equity-Based Compensation Plan, increasing available shares by 3,935,000.BDX reported record FY2025 revenue of $21.8 billion, with 7.7% adjusted growth and 2.9% organic growth.BDX is undervalued by 38.5% according to a discounted cash flow analysis, with recent stock declines of 2.1% over seven days and 16.4% over one year.BDX and Envetec completed a feasibility study to recycle medical plastics into manufacturing feedstock, enabling sustainable reuse of materials.

Recent Updates

BDX News